NEW BRUNSWICK, N.J. (AP) — Johnson & Johnson’s third-quarter profit jumped 23%, beating Wall Street forecasts, thanks to higher sales of its key medicines for cancer and immune disorders and an acquisition-related charge a year earlier.
The world’s biggest maker of health care products also raised its financial forecast for the year, and its shares jumped more than 2% in premarket action.
J&J on Tuesday reported net income of $4.83 billion, or $1.81 per share. That was up from $3.93 billion, or $1.44 per share, in 2018’s third quarter, when the drugmaker took a $1.13 billion charge related to research programs acquired with its purchase of Alios BioPharma.
Earnings, adjusted for one-time gains and costs, came to $2.12 per share, easily topping analysts’ projections for $2, according to a survey of analysts by Zacks Investment Research.
Revenue of $20.73 billion, up 2% from $20.35 billion a year ago, also beat forecasts.
J&J’s prescription drugs business boosted sales 5% to $10.88 billion, led by cancer drugs Darzalex and Imbruvica and by Simponi, Stelara and Tremfya, which treat immune system disorders such as psoriasis, rheumatoid arthritis and Crohn’s disease.
The consumer products business, which makes Johnson’s baby shampoo, Neutrogena and Aveeno skin care products and pain relievers Tylenol and Motrin, posted a 1.6% increase in sales, to $3.47 billion. The medical device and diagnostics business, once J&J’s biggest segment, saw sales drop 3% to $6.38 billion.
The New Brunswick, New Jersey company forecast 2019 per-share earnings of $8.62 to $8.67, after adjustments for one-time items, and revenue of between $81.8 billion and $82.3 billion. In July, the company forecast adjusted per-share earnings between $8.53 and $8.63, and revenue between $80.8 billion and $81.6 billion.
During the third quarter, Johnson & Johnson received approval from the U.S. Food and Drug Administration for additional uses for four of its medicines: blood thinner Xarelto, Type 2 diabetes pill Invokana, prostate cancer drug Erleada and Darzalex, for treating blood cancer multiple myeloma. In the European Union, Stelara received approval for treating ulcerative colitis and cancer drug Imbruvica won approval for two more uses. J&J also launched two new medical devices, a surgical stapler and a new version of its Attune knee replacement system.
In premarket trading, J&J shares jumped $2.38, or 1.8%, to $133.10.
Follow Linda A. Johnson at https://twitter.com/LindaJ—onPharma
Portions of this story were generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research.
Copyright 2019 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
- Daimler in fresh profit warning over Dieselgate, faulty airbags
- Boris Johnson stokes multinational tax debate
- Nigel Farage IS 'in secret talks with Boris Johnson to pull the majority of Brexit Party candidates out of the election - in return for the PM negotiating a harder deal
- Boris Johnson gets election boost as the UK economy swings out of recession danger - growing 0.4pc in the last quarter
- Johnson beats Livingstone to become mayor of London
- Government lawyers warn Boris Johnson Britain COULD still have to pay the full £39 billion Brexit divorce bill even if it leaves with No Deal
- Only Boris Johnson can deliver Brexit and save the economy from Jeremy Corbyn
- The impact of credit policies on Viet Nam’s banking outlook
- Ryanair profits slump 29% due to fare and costs turbulence
- Moody's downgrades UK's credit outlook after Brexit 'paralysis'
- Brazil's Iguatemi sees higher October sales after topping quarterly profit estimates
- Jabari Parker Delivers Over $13.5 in DFS Profit... Jarrett Allen Crushes DFS Owners
- Join Jeremy Johnson from Andela at Disrupt Berlin
- Ashish Chugh: How to spot multibaggers and when to exit a stock
- Trump suggests 'second thoughts' about China tariff war, triggers confusion at G-7 summit
- D-Street week ahead: Stellar GDP print may lift market momentum
- UK avoids recession but economy growing at near decade lows
- Inside 'Billionaires Row': London's rotting, derelict mansions worth £350m
- Labour pledges massive investment in 37 offshore wind farms creating 67,000 jobs
- Will Farage do a deal with the Tories? Arron Banks claims parties have held secret talks in bid to stop Leave vote being split and gifting election victory to Corbyn
Higher 3Q profit, improved outlook for Johnson & Johnson have 656 words, post on gazette.com at October 15, 2019. This is cached page on Talk Vietnam. If you want remove this page, please contact us.